Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)
Primary Purpose
Rheumatoid Arthritis
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
MK0359
Sponsored by

About this trial
This is an interventional treatment trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria:
- You are 18-65 years of age and have Rheumatoid Arthritis
- You must be able to read and understand patient questionnaires
Exclusion Criteria:
- You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00482417
First Posted
June 1, 2007
Last Updated
November 19, 2015
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00482417
Brief Title
Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
December 2002 (undefined)
Primary Completion Date
May 2003 (Actual)
Study Completion Date
May 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
Efficacy and Safety Study of MK0359 in Patients with Arthritis
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
MK0359
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
You are 18-65 years of age and have Rheumatoid Arthritis
You must be able to read and understand patient questionnaires
Exclusion Criteria:
You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)
We'll reach out to this number within 24 hrs